Sunitinib D4
| Product Name | Sunitinib D4 |
|---|---|
| Alternate Names | Sunitinib Stable Isotopes, Stable Isotopes of Sunitinib |
| CAT No. | CS-O-10804 |
| CAS No. | 1126721-79-6 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 402.50 g/mol |
| Mol. For. | C₂₂H₂₃D₄FN₄O₂ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Sunitinib |
| Purity | 95% |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | O=C1/C(C2=CC(F)=CC=C2N1)=C\C(NC(C)=C3C(NC([2H])([2H])C([2H])([2H])N(CC)CC)=O)=C3C |
| Canonical Smiles | CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C |
| InchIKey | WINHZLLDWRZWRT-IMVYMHHKSA-N |
| Inchl | InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-/i9D2,10D2 |
| IUPAC | 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[1,1,2,2-tetradeuterio-2-(diethylamino)ethyl]-1H-pyrrole-3-carboxamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Sunitinib D4 is a deuterated form of Sunitinib, a small molecule drug that functions as a multi-targeted receptor tyrosine kinase inhibitor. It is used in the treatment of advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Sunitinib D4 is an isotopically labeled form of the drug, containing a higher percentage of deuterium atoms than the non-deuterated form.
The chemical structure of Sunitinib D4 is C22H17D4ClN4O, and its molecular weight is 406.9 g/mol. It is a yellow to orange powder that is slightly soluble in water. The deuterium atoms in Sunitinib D4 serve to increase its stability and decrease its metabolism rate, resulting in a longer half-life and improved pharmacokinetic properties compared to the non-deuterated form.
Sunitinib D4 works by inhibiting the activity of various receptor tyrosine kinases, such as vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and stem cell factor receptor (KIT). By inhibiting these receptors, Sunitinib D4 blocks the growth and division of cancer cells, as well as preventing the formation of new blood vessels that tumors rely on for nutrients and oxygen.
In conclusion, Sunitinib D4 is an important drug used in the treatment of several types of cancer. Its deuterated form provides improved pharmacokinetic properties and stability, allowing for more effective treatment outcomes.
Get an Instant Quote
Related Compounds
N-Desethyl Sunitinib-d5 | Sunitinib D10 | N,N-Didesethyl Sunitinib-d4 Hydrochloride |